健康险开新局：浮动收益型渐行渐近 支持创新药多元支付

Core Insights - The National Financial Regulatory Administration has issued guidelines to promote high-quality development in health insurance, addressing existing issues such as product homogeneity and insufficient industry capabilities [1][4] - Experts believe that floating yield health insurance can resolve structural contradictions in long-term medical insurance development, while innovative payment mechanisms for drugs and medical devices can facilitate cooperation among insurance companies, hospitals, and pharmaceutical firms [1][7] Group 1: Development of Long-term Health Insurance - The guidelines encourage the development of dividend-based long-term health insurance to enhance service levels and support floating yield products as a key development direction [3][4] - There is a significant need for long-term health insurance in China, as the current market heavily favors critical illness insurance, with long-term medical insurance being underrepresented [5][6] Group 2: Floating Yield Products - Dividend-based long-term health insurance alleviates concerns for insurance companies while meeting consumer demand for long-term coverage, balancing risks and market appeal [6][8] - The floating yield mechanism allows insurance companies to manage risks during periods of declining interest rates, making it a potential product for long-term holders [6][8] Group 3: Innovative Payment Mechanisms for Drugs - The guidelines propose flexible payment methods for innovative drugs, including market-based negotiations and payment by efficacy, to enhance accessibility and affordability [7][9] - The current conflict of interest between commercial health insurance and pharmaceutical companies highlights the need for a mechanism that ensures fair profit distribution among insurers, hospitals, and drug manufacturers [8][9]